About
Hanmi Pharm Co Ltd. is a leading biopharmaceutical company based in Seoul, South Korea. Since its establishment in 1973, the company has focused on the development and marketing of innovative therapeutics for the treatment of serious diseases. The history of Hanmi Pharm is characterized by continuous growth and groundbreaking successes. Over the past 50 years, the company has become a key player in the biopharmaceutical industry, with branches in Europe, America, and Asia. Hanmi Pharm's business model is focused on developing and selling innovative drugs that target core competencies such as oncology, immunology, metabolic diseases, and rare diseases. The company has several research facilities where highly qualified scientists work to develop new and more effective therapies. Hanmi Pharm is divided into three different divisions: drug development, manufacturing, and distribution. In the drug development division, the company works on discovering new compounds and medications for the treatment of various diseases. In the manufacturing division, the company produces the corresponding drugs under the highest quality standards. In the distribution area, Hanmi Pharm distributes its products worldwide and ensures that they always meet the high requirements of regulatory authorities. In recent years, Hanmi Pharm has brought an impressive range of products to the market, including drugs for the treatment of cancer, diabetes, cardiovascular diseases, and other serious conditions. Here are some of the company's most well-known products: - Lapsiratase: A novel drug for the treatment of acute myeloid leukemia. Lapsiratase was developed by Hanmi Pharm in partnership with a European company and has already shown promising results in clinical trials. - Insulin Glargine: A basal insulin analog used for the treatment of diabetes. The medication is approved in Europe and Canada and is manufactured by Hanmi Pharm in collaboration with a European company. - Olita (Olmesartan medoxomil): An antihypertensive drug prescribed for the treatment of high blood pressure. Olita is a well-known medication from Hanmi Pharm and is distributed worldwide. - Biosimilars: In recent years, Hanmi Pharm has also invested extensively in the development of biosimilars. These biological imitations of original drugs are a cost-effective alternative to expensive biopharmaceuticals and can provide many patients with access to crucial therapy options. Hanmi Pharm aims to continue developing and bringing innovative drugs to the market that improve people's lives and provide better treatment options for seriously ill patients.
Annual results
Reported figures, KRW · revenue up 3.5% in 2025
| Year | Revenue | Net income | Net margin | Free cash flow |
|---|---|---|---|---|
| 2025 | 1.5T | 170B | 11.0% | — |
| 2024 | 1.5T | 121B | 8.1% | — |
| 2023 | 1.5T | 146B | 9.8% | — |
| 2022 | 1.3T | 82.8B | 6.2% | — |
| 2021 | 1.2T | 67.0B | 5.6% | — |
Dividends per share
128940.KS in MarketPulse
The live chart with RSI and moving averages, the price, news, signals and price alerts for Hanmi Pharm Co Ltd are inside MarketPulse — currently in private beta.
Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.